[go: up one dir, main page]

AR037951A1 - Composiciones farmaceuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada - Google Patents

Composiciones farmaceuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada

Info

Publication number
AR037951A1
AR037951A1 ARP020105039A ARP020105039A AR037951A1 AR 037951 A1 AR037951 A1 AR 037951A1 AR P020105039 A ARP020105039 A AR P020105039A AR P020105039 A ARP020105039 A AR P020105039A AR 037951 A1 AR037951 A1 AR 037951A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
orxally
active
taxane derivative
biodisponibility
Prior art date
Application number
ARP020105039A
Other languages
English (en)
Inventor
Joseph Ballard Bogardus
Robert Kevin Perrone
Sailesh A Varia
Krishnaswamy S Raghavan
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR037951A1 publication Critical patent/AR037951A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composiciones farmacéuticas que comprenden un derivado de taxano oralmente activo y un agente de solubilización farmacéuticamente aceptable, y que proporciona absorción oral efectiva y consistente del derivado de taxano. Reivindicación 1: Una composición farmacéutica caracterizada porque comprende un derivado de taxano oralmente activo que tiene las fórmulas (1) y (2), en donde: R es fenilo, isopropilo, o ter-butilo; R1 es -C(O)Rz en la cual Rz es (CH3)3CO-, (CH3)3CCH2-, CH3(CH2)3O-, ciclobutilo-, ciclohexiloxi, o (2-furilo); y R2 es CH3C(O)O-, y un agente de solubilización farmacéuticamente aceptable para dicho derivado de taxano.
ARP020105039A 2001-12-20 2002-12-19 Composiciones farmaceuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada AR037951A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34288901P 2001-12-20 2001-12-20

Publications (1)

Publication Number Publication Date
AR037951A1 true AR037951A1 (es) 2004-12-22

Family

ID=23343716

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020105039A AR037951A1 (es) 2001-12-20 2002-12-19 Composiciones farmaceuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada

Country Status (24)

Country Link
US (1) US20030220391A1 (es)
EP (1) EP1465618A2 (es)
JP (1) JP2006501134A (es)
KR (1) KR20040066921A (es)
CN (1) CN1273130C (es)
AR (1) AR037951A1 (es)
AU (1) AU2002361701A1 (es)
BR (1) BR0215184A (es)
CA (1) CA2470826A1 (es)
GE (1) GEP20063806B (es)
HR (1) HRP20040545A2 (es)
HU (1) HUP0500843A2 (es)
IL (1) IL162118A0 (es)
IS (1) IS7306A (es)
MX (1) MXPA04005877A (es)
NO (1) NO20043101L (es)
PE (1) PE20030742A1 (es)
PL (1) PL374283A1 (es)
RS (1) RS52904A (es)
RU (1) RU2004119557A (es)
TW (1) TW200302086A (es)
UY (1) UY27598A1 (es)
WO (1) WO2003053350A2 (es)
ZA (1) ZA200404584B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1642576A (zh) * 2002-02-25 2005-07-20 药物发展有限公司 吸收增强剂
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
KR100533458B1 (ko) * 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
EP1498120A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
EP1785416A3 (en) 2003-09-25 2007-05-30 Tapestry Pharmaceuticals, Inc. 9, 10-alpha, alpha-OH-Taxane Analogs and methods for production thereof
US20060088591A1 (en) * 2004-10-22 2006-04-27 Jinghua Yuan Tablets from a poorly compressible substance
WO2006058121A1 (en) * 2004-11-23 2006-06-01 Bristol-Myers Squibb Company Crystalline forms of 3'-tert-butyl-3'-n-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-n-debenzoyl-4-o-methoxycarbonyl-paclitaxel
EP2896412A1 (en) * 2005-02-18 2015-07-22 Abraxis BioScience, LLC Drugs with improved hydrophobicity for incorporation in medical devices
AU2012202903B2 (en) * 2005-02-18 2014-12-11 Abraxis Bioscience, Inc. Drugs with improved hydrophobicity for incorporation in medical devices
JP5436856B2 (ja) * 2005-07-15 2014-03-05 アンジオケム インコーポレーティッド 薬学的複合体における担体としてのアプロチニンポリペプチドの使用
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
ES2784794T3 (es) 2005-08-31 2020-10-01 Abraxis Bioscience Llc Composiciones que comprenden agentes farmacéuticos poco solubles en agua y agentes antimicrobianos
WO2007134354A1 (de) * 2006-05-23 2007-11-29 Ebewe Pharma Ges.M.B.H. Nfg. Kg Pharmazeutische formulierung
WO2008106621A1 (en) 2007-02-28 2008-09-04 Tapestry Pharmaceuticals, Inc Taxane analogs for the treatment of brain cancer
US11786504B2 (en) 2006-09-28 2023-10-17 Tapestry Pharmaceuticals, Inc. Taxane analogs for the treatment of brain cancer
WO2008121476A1 (en) 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
US11873308B2 (en) 2006-11-06 2024-01-16 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
EP1946747A1 (en) * 2007-01-17 2008-07-23 Sandoz AG Pharmaceutical composition of improved stability containing taxane derivatives
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
AU2008291930B2 (en) * 2007-08-24 2014-04-17 Slotervaart Participaties Bv Compositions for the treatment of neoplastic diseases
EP2316422A1 (en) * 2007-11-12 2011-05-04 Novartis AG Liquid compositions comprising valsartan
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
ES2344674B1 (es) 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
CN102245642A (zh) 2008-10-15 2011-11-16 安吉奥开米公司 Glp-1激动剂的结合物及其用途
EP2662472B1 (de) 2009-03-31 2019-02-27 Boehringer Ingelheim International Gmbh Verfahren zur Beschichtung einer Oberfläche eines Bauteils
WO2010133294A2 (de) 2009-05-18 2010-11-25 Boehringer Ingelheim International Gmbh Adapter, inhalationseinrichtung und zerstäuber
CN102038635A (zh) 2009-10-23 2011-05-04 天津天士力集团有限公司 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
EP2504051B1 (en) 2009-11-25 2019-09-04 Boehringer Ingelheim International GmbH Nebulizer
JP5715640B2 (ja) 2009-11-25 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
WO2011160932A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Nebulizer
EP2694220B1 (de) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
EP2777691A1 (en) * 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
WO2015018904A1 (en) 2013-08-09 2015-02-12 Boehringer Ingelheim International Gmbh Nebulizer
ES2836977T3 (es) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizador
KR102730574B1 (ko) 2014-05-07 2024-11-15 베링거 인겔하임 인터내셔날 게엠베하 분무기, 표시 디바이스 및 컨테이너
BR112016023983B1 (pt) 2014-05-07 2022-10-18 Boehringer Ingelheim International Gmbh Contentor para um nebulizador, nebulizador para um fluido e método para conectar um contentor a um dispositivo indicador
US10722666B2 (en) 2014-05-07 2020-07-28 Boehringer Ingelheim International Gmbh Nebulizer with axially movable and lockable container and indicator
CN103980232A (zh) * 2014-06-05 2014-08-13 北京诺普德医药科技有限公司 10-乙酰基多西紫杉醇及其用途
JP6823055B2 (ja) 2015-06-15 2021-01-27 アンジオケム インコーポレーテッド 軟髄膜癌腫症の治療方法
TWI715636B (zh) * 2015-09-30 2021-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
CN108066335B (zh) * 2016-11-11 2020-02-21 北京康辰药业股份有限公司 一种含有紫杉醇或其类似物的药物组合物及其制备方法
FR3113238B1 (fr) 2020-08-05 2024-04-05 Gattefosse Sas Utilisation comme excipient, d’un melange de macrogolglyceride laurique et de polyethylene glycol

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
DK0835657T3 (da) * 1992-11-27 2005-01-10 Mayne Pharma Usa Inc Stabil, injicerbar paclitaxelsammensætning
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6395770B1 (en) * 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
IL126179A (en) * 1996-03-12 2003-04-10 Pg Txl Co Lp Pharmaceutical compositions containing anti-tumor drug conjugates
US5756537A (en) * 1996-11-08 1998-05-26 Parkash S. Gill, M.D., Inc. Regime for paclitaxel in Kaposi's sarcoma patients
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US5980936A (en) * 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
HUP0101457A3 (en) * 1997-12-31 2003-01-28 Bristol Myers Squibb Co Antitumor 2-aroyl-4-acyl paclitaxel analogs and medicaments containing them , their intermediates and method for producing them
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
CA2373819A1 (en) * 1999-05-17 2000-11-23 Bristol-Myers Squibb Company Novel reaction conditions for the cleavage of silyl ethers in the preparation of paclitaxel (taxol) and paclitaxel analogues
JP2003506446A (ja) * 1999-08-11 2003-02-18 ブリストル−マイヤーズ スクイブ カンパニー パクリタキセルｃ−４メチルカーボネート類縁体の製造法
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6916942B2 (en) * 2000-02-03 2005-07-12 Bristol-Myers Squibb Company Process for the preparation of C-4 carbonate taxanes
US6750246B1 (en) * 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US6919370B2 (en) * 2000-11-28 2005-07-19 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
TWI297335B (en) * 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof

Also Published As

Publication number Publication date
WO2003053350A3 (en) 2004-01-15
RU2004119557A (ru) 2005-04-20
GEP20063806B (en) 2006-04-25
WO2003053350A2 (en) 2003-07-03
JP2006501134A (ja) 2006-01-12
PE20030742A1 (es) 2003-09-02
KR20040066921A (ko) 2004-07-27
NO20043101L (no) 2004-07-19
US20030220391A1 (en) 2003-11-27
RS52904A (sr) 2006-12-15
CN1273130C (zh) 2006-09-06
EP1465618A2 (en) 2004-10-13
MXPA04005877A (es) 2004-09-13
CN1606437A (zh) 2005-04-13
UY27598A1 (es) 2003-07-31
IL162118A0 (en) 2005-11-20
ZA200404584B (en) 2005-09-13
HRP20040545A2 (en) 2005-08-31
TW200302086A (en) 2003-08-01
BR0215184A (pt) 2006-06-06
IS7306A (is) 2004-06-10
PL374283A1 (en) 2005-10-03
CA2470826A1 (en) 2003-07-03
AU2002361701A1 (en) 2003-07-09
HUP0500843A2 (hu) 2005-12-28

Similar Documents

Publication Publication Date Title
AR037951A1 (es) Composiciones farmaceuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada
CY1108522T1 (el) Μεθοδος συνθεσης της περινδοπριλης και των φαρμακευτικως αποδεκτων αλατων της
EA200300323A1 (ru) ПРОИЗВОДНЫЕ ГУАНИДИНОБЕНЗАМИДА (ВАРИАНТЫ), КОМПОЗИЦИЯ (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ ОПОСРЕДОВАННОГО mc4-r ЗАБОЛЕВАНИЯ (ВАРИАНТЫ)
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
NO20073764L (no) Sammensetninger for behandling av HCV
EA200201262A1 (ru) Композиции для лечения флавивирусных и пестивирусных инфекций и способы их применения
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
PE20100363A1 (es) Composiciones que comprenden nucleosidos
DE602004030689D1 (de) Verbindungen gegen entzündungen und immun-relevante verwendungen
ATE485290T1 (de) Platelet adp rezeptor inhibitoren
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
FI964285A0 (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
CO5590918A2 (es) Formulaciones
DK1296972T3 (da) Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer
AR034343A1 (es) Combinaciones farmaceuticas
DK1251846T3 (da) C4-Carbonattaxaner
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
ATE365735T1 (de) Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel
DE60120427D1 (de) Radicicol und monocillin und ihre analogen und ihre anwendungen
CO5590911A2 (es) Composiciones farmaceuticas a base de derivados de azetidina
ECSP034561A (es) Derivados puente de piperazina
SE0003476D0 (sv) Compounds
AR035110A1 (es) Compuesto derivado de piperazina, uso del mismo para la preparacion de una composicion farmaceutica, composicion farmaceutica que lo comprende y procedimiento para la preparacion de dicho compuesto
BR0315016A (pt) Composição fumìgena

Legal Events

Date Code Title Description
FB Suspension of granting procedure